Back to top

gene-therapy: Archive

Ekta Bagri

3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

BEAMPositive Net Change NTLANegative Net Change KRYSNegative Net Change MGTXNegative Net Change

Zacks Equity Research

KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.

BAYRYNegative Net Change AGENNegative Net Change KRYSNegative Net Change IMCRPositive Net Change

Sundeep Ganoria

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

REGNPositive Net Change VRTXPositive Net Change NTLANegative Net Change CRSPPositive Net Change

Ahan Chakraborty

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

SNYPositive Net Change NVOPositive Net Change LLYPositive Net Change VERVNegative Net Change

Sundeep Ganoria

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.

NVSPositive Net Change BMYPositive Net Change VRTXPositive Net Change BEAMPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.

SNYPositive Net Change BMYPositive Net Change LLYPositive Net Change VERVNegative Net Change

Zacks Equity Research

SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion

Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.

RHHBYNegative Net Change SRPTPositive Net Change AGENNegative Net Change IMCRPositive Net Change